Veeva to deliver the only clinical suite that unifies CTMS and eTMF
for one process, one system, and one view across clinical trials in the
cloud
PLEASANTON, Calif.--(BUSINESS WIRE)--
Veeva
Systems (NYSE: VEEV) today introduced Veeva
Vault CTMS, the industry’s first multitenant cloud application that
unifies information, documentation, and processes globally for a single
source of truth across clinical operations. Together with Veeva
Vault eTMF, Veeva will offer the first and only suite of clinical
applications that combines CTMS and eTMF on one cloud platform. Now life
sciences companies can accelerate trial execution and gain real-time
visibility into their clinical operations.
“The clinical development process is highly inefficient due to a number
of factors, including the inconsistent use of a large number of
disparate and incompatible technologies,” said Ken Getz, associate
professor at Tufts University School of Medicine and chairman of the
Center for Information and Study on Clinical Research Participation.
“Transparency, compatibility, and integration are critical factors
driving technology solutions adoption among clinical research
professionals, patients, and the broader health care environment.”
The fragmented landscape in clinical operations stems from duplicate
content and data in multiple systems across many processes in a growing,
complex global ecosystem of stakeholders. System and process silos
create challenges for operations leaders to plan and make informed
decisions during clinical trials.
“Veeva is bringing the next generation of clinical trial management to
life sciences,” said Jennifer Goldsmith, senior vice president of Veeva
Vault. “We are filling a significant gap in the industry with a unified
suite of applications to provide one process, one system, and one view
within and across clinical trials. For the first time, life sciences
companies will be able to get full visibility into their clinical
operations.”
Veeva Vault CTMS will help life sciences companies unify their clinical
trial operations to reduce complexity, increase transparency, and speed
time-to-market by providing:
-
One source for clinical master data – ensure high-quality data
across clinical applications with one system of record for study,
study country, and study site information
-
Real-time visibility – make faster, more informed decisions
with a comprehensive, accurate view into the performance and
efficiency of clinical trials
-
Seamless access – enable collaboration across critical
stakeholders from sponsors to CROs to investigator sites with a single
solution in the cloud
-
A true cloud solution – always current with the latest system
capabilities without disruptive upgrades that can impact trial
execution
In a recent survey of eTMF owners, 49% cited integration between their
eTMF and CTMS applications as a key need. Veeva Vault CTMS joins Vault
eTMF and Veeva
Vault Study Startup as part of the Vault Clinical Suite designed to
unify clinical operations. Vault CTMS is the latest application built on Veeva
Vault, a cloud platform and suite of applications specifically built
for life sciences. Traditionally, companies deploy multiple applications
to manage content and the associated data. Veeva Vault is the only
content management platform with the unique capability to manage both
content and data. Now life sciences companies can eliminate system,
site, and country silos and streamline their end-to-end clinical
processes.
Vault CTMS is expected to be available in the first quarter of 2017.
Additional Information
For more on Veeva Vault CTMS: veeva.com/VaultCTMS
For
more on Veeva Vault Clinical Suite: veeva.com/VaultClinical
Stay
updated on the latest Veeva news on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in
cloud-based software for the global life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva has more
than 400 customers, ranging from the world's largest pharmaceutical
companies to emerging biotechs. Veeva is headquartered in the San
Francisco Bay Area, with offices in Europe, Asia, and Latin America. For
more information, visit veeva.com.
Forward-looking Statements
This release contains
forward-looking statements, including the market demand for and
acceptance of Veeva’s products and services, the results from use of
Veeva’s products and services, and general business conditions,
particularly in the life sciences industry. Any forward-looking
statements contained in this press release are based upon Veeva’s
historical performance and its current plans, estimates, and
expectations, and are not a representation that such plans, estimates,
or expectations will be achieved. These forward-looking statements
represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in the company’s filing on Form
10-Q for the period ended April 30, 2016. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160622005354/en/
Source: Veeva Systems